|

Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas

RECRUITINGPhase 2Sponsored by Proton Collaborative Group
Actively Recruiting
PhasePhase 2
SponsorProton Collaborative Group
Started2016-04
Est. completion2039-10
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations4 sites

Summary

The prognosis for patients with localized pancreatic adenocarcinoma who are not surgical candidates is poor. Patients characterized as having "borderline resectable" disease treated with preoperative chemo-radiotherapy fair somewhat better - although many of these patients are not converted to resectability. It may be argued that intensification of local and regional therapy might 1.) Increase the share of patients able to undergo curative surgery and 2.) Improve the local disease control interval and extend survival for patients who remain unresectable. Therefore, the purpose of this research study is to determine if an increase in the number of surgical resection pancreatic adenocarcinoma is higher than historical data by using a combined treatment of proton radiation with capecitabine (oral chemotherapy).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Biopsy proven unresectable adenocarcinoma of the pancreas.
* Have either unresectable, borderline resectable or medically inoperable carcinoma of the pancreas, or refusing surgery.
* A biliary obstruction is able to participate as long as a drainage tube is in place prior to starting treatment with Proton radiation,
* Participants of child-producing potential must be willing to use contraception while on treatment and for at least 12 months thereafter.
* Required pretreatment laboratory parameters:

  * Absolute granulocyte count (AGC/ANC) ≥ 1.8 thou/mm3
  * Platelet count ≥ 100,000/mm3
  * Bilirubin \< 2 mg/dl
  * ALT/SGPT \< 3x upper limit of normal
  * Creatinine \< 3 mg/dl

Exclusion Criteria:

* Evidence of distant metastasis.
* Prior surgical resection.
* Previous history of invasive malignancy (except non-melanoma skin cancer and low to intermediate risk prostate cancer) unless the participant has been disease free for 5 years prior to registration.
* Active or untreated infection,
* Pregnant or breastfeeding women or subjects of child producing potential not willing to use medically acceptable contraception while on treatment and for at least 12 months thereafter.
* Previous Radiation to the abdomen.

Conditions2

CancerPancreatic Cancer

Locations4 sites

Florida

1 site
University of Florida Proton Therapy Institute
Jacksonville, Florida, 32206

Illinois

1 site
Northwestern Medicine Chicago Proton Center
Warrenville, Illinois, 60555
Don Smith, MS, CCRC630-933-7820donald.smith3@nm.org

Michigan

1 site
McLaren Proton Therapy Center
Flint, Michigan, 48532
Taylor Brewer313-576-8526brewert@karmanos.org

Virginia

1 site
Inova Schar Cancer Institute
Fairfax, Virginia, 22031
Sangeetha Moturi571-472-0343sangeetha.moturi@inova.org

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.